GNPX
Genprex, Inc.NASDAQHealthcare$1.54-5.84%ClosedMarket Cap: $2.5M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.17
P/S
0.00
EV/EBITDA
0.34
DCF Value
$7.64
FCF Yield
-647.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-464.1%
ROA
-159.7%
ROIC
-194.3%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-3.8M | $9.10 |
| FY 2025 | $0.00 | $-16.2M | $-17.40 |
| Q3 2025 | $0.00 | $-3.8M | $-5.00 |
| Q2 2025 | $0.00 | $-4.7M | $-8.50 |
Trading Activity
Insider Trades
View AllBerger Mark Stanleyofficer: Chief Medical Officer
SellFri Feb 27
Confer Ryan M.director, officer: President, CEO and CFO
SellFri Feb 27
Moreno Toscano Jose Antoniodirector
SellTue Dec 23
Berger Mark Stanleyofficer: Chief Medical Officer
SellTue Dec 23
Confer Ryan M.director, officer: President, CEO and CFO
SellTue Dec 23
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-0.75
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.